Table 3.
Baseline characteristics by study completion and treatment group.
| Treatment Group | |||
|---|---|---|---|
| Characteristics | Study Completion | Placebo | Escitalopram |
| Mean(SD) | Mean(SD) | ||
| Age | Completer (n = 77) | 46.69(10.78) | 44.58(12.14) |
| Drop out (n = 62) | 41.52(11.78) | 43.09(12.22) | |
| n | n | ||
| Sex | |||
| Male | Completer (n = 20) | 11 | 9 |
| Drop out (n = 19) | 13 | 6 | |
| Female | Completer (n = 52) | 28 | 29 |
| Drop out (n = 43) | 16 | 27 | |
| Ethnicity | |||
| Caucasian | Completer (n = 14) | 7 | 7 |
| Drop out (n = 8) | 5 | 3 | |
| African American | Completer (n = 49) | 25 | 24 |
| Drop out (n = 34) | 14 | 20 | |
| Hispanic | Completer (n = 11) | 6 | 5 |
| Drop out (n = 20) | 10 | 10 | |
| Asian/Pacific Islander | Completer (n = 2) | 1 | 1 |
| Drop out (n = 0) | 0 | 0 | |
| Asthma/Depression Severity | |||
| High | Completer (n = 21) | 10 | 11 |
| Drop out (n = 21) | 10 | 11 | |
| Low | Completer (n = 56) | 29 | 27 |
| Drop out (n = 41) | 19 | 22 | |
| Mean(SD) | Mean(SD) | ||
| HRSD17 Baseline | Completer (n = 77) | 24.85(5.09) | 25.03(5.23) |
| Drop out (n = 62) | 26.97(4.86) | 26.12(4.99) | |
| IDS-SR Baseline | Completer (n = 77) | 37.61(12.25) | 36.84(11.69) |
| Drop out (n = 62) | 38.28(10.97) | 40.06(12.48) | |
Note: In drop outs there were significantly more women (81.8%) in the escitalopram group compared to men (18.2%), χ2 (1) = 5.16, p = .02. There were no other statistically significant differences between groups on baseline characteristics. HRSD17 – Hamilton Rating Scale for Depression; IDS-SR – Inventory of Depressive Symptomatology Self-Report.